Reduced Seminal Concentration of CD45pos Cells after Follicle-Stimulating Hormone Treatment in Selected Patients with Idiopathic Oligoasthenoteratozoospermia

Table 4

The percentage distribution of patients according to the different concentrations of CD45pos cells before and after therapy.

CD45pos cells	Group A; (𝑛=20 patients)	Group B; (𝑛=20 patients)	Group C; (𝑛=14 patients)
Before treatment
0.1–0.5 mil/mL	2 (10%)	2 (10%)	1 (7%)
0.5–1.0 mil/mL	3 (15%)	3 (15%)	2 (14%)
1.0–1.5 mil/mL	3 (15%)	5 (25%)	2 (14%)
1.5–2.0 mil/mL	8 (40%)*	7 (35%)*	7 (50%)*
2.0–2.5 mil/mL	2 (10%)	2 (10%)	1 (7%)
2.5–3.0 mil/mL	2 (10%)	1 (5%)	1 (7%)
After treatment
0.1–0.5 mil/mL	14 (70%)*	15 (75%)*	9 (64%)*
0.5–1.0 mil/mL	2 (10%)	1 (5%)	1 (7%)
1.0–1.5 mil/mL	1 (5%)	1 (5%)	1 (7%)
1.5–2.0 mil/mL	1 (5%)	1 (5%)	1 (7%)
2.0–2.5 mil/mL	1 (5%)	1 (5%)	1 (7%)
2.5–3.0 mil/mL	1 (5%)	1 (5%)	1 (7%)

^∗𝑃<0.05 versus other concentrations.